Study Microvascular outcome Relative RR Absolute RR NNT p-value FIELD [41] [N=9,795] First laser treatment for retinopathy 31% 1.5% 67 0.002 FIELD substudy[41] [N=1,012] i) DR progression, i.e. ≥2 steps of the ETDRS,macular edema or laser treatment  ii) ≥2 steps of the ETDRS All patients Pre-existing retinopathy No pre-existing retinopathy   31% 22% 79% 2.6% 5.0% 2.7% 11.5% 0.3% 20 37 9 333 0.022 0.19 0.004* 0.87* ACCORD-EYE [3] [N= 1,593] DR progression, i.e. ≥3 steps of the ETDRS or proliferative DR requiring laser therapy or vitrectomy 40% 3.7% 27 0.006

*treatment versus retinopathy status interaction, p=0.019; NNT number needed to treat = 1/absolute risk reduction; RR risk reduction; ETDRS Early Treatment Diabetic Retinopathy Study scale; FIELD: Fenofibrate Intervention and Event Lowering in Diabetes; ACCORD: Action to Control Cardiovascular Risk in Diabetes

Table 3: Effects of fenofibrate on Diabetic Retinopathy (DR) progression: Summary of results from the FIELD and ACCORD-Eye studies [13,41].